Charlotte Passemar

Charlotte Passemar

Auto-generated profile, based on publicly available information

Charlotte Passemar

Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK; Victor Philip Dahdaleh Heart & Lung Research Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
JBJosephine M. Bryant
Josephine M. Bryant
KBKaren P. Brown
Karen P. Brown
SBSophie Burbaud
Sophie Burbaud
IEIsobel Everall
Isobel Everall
Juan BelardinelliJuan Belardinelli
Juan Belardinelli
RFR. Andres Floto
R. Andres Floto
Jump starting pathogen evolution: Mycobacteria are mostly environmental saprotrophs, but during human history, some have become our pathogens. In the past 50 years or so, intractable and virulent infections of Mycobacterium abscessus have emerged in people with cystic fibrosis. Bryant et al. investigated how these mycobacteria have evolved into human pathogens so quickly (see the Perspective by Brugha and Spencer). Chronic infections in the lung offer plenty of evolutionary scope for the emergence of virulent clones after horizontal gene transfer and hypermutation. Pathogens are acquired by environmental contamination, which leaves open a window for clinical control because the most virulent clones survive poorly outside the body. Therefore, immediate treatment and enhanced infection-control measures for M. abscessus cases could reduce opportunities for the evolution of direct person-to-person transmission. Science , this issue p. eabb8699 ; see also p. 465

6 May 2025 in Cell Reports
Verified
Journal Article
Open access
CMCharlotte Maserumule
Charlotte Maserumule
CPCharlotte Passemar
Charlotte Passemar
OOOlivia S.H. Oh
Olivia S.H. Oh
KHKriztina Hegyi
Kriztina Hegyi
KBKaren Brown
Karen Brown
RFR. Andres Floto
R. Andres Floto
Genetic determinants of susceptibility to Mycobacterium tuberculosis (Mtb) remain poorly understood but could provide insights into critical pathways involved in infection, informing host-directed therapies and enabling risk stratification at individual and population levels. Through a genome-wide forward genetic screen, we identify Toll-like receptor 8 (TLR8) as a key regulator of intracellular killing of Mtb. Pharmacological TLR8 activation enhances the killing of phylogenetically diverse clinical isolates of drug-susceptible and multidrug-resistant Mtb by macrophages and during in vivo infection in mice. TLR8 is activated by phagosomal mycobacterial RNA released by extracellular membrane vesicles and enhances xenophagy-dependent Mtb killing. We find that the TLR8 variant M1V, common in Far Eastern populations, enhances intracellular killing of Mtb through preferential signal-dependent trafficking to phagosomes. TLR8 signaling may, therefore, both regulate susceptibility to tuberculosis and provide novel drug targets.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
RPRemi Planes
Remi Planes
MMMiriam Pinilla Marquinez
Miriam Pinilla Marquinez
KSKarin Santoni
Karin Santoni
AHAudrey Hessel
Audrey Hessel
CPCharlotte Passemar
Charlotte Passemar
EMEtienne Meunier
Etienne Meunier
Inflammation observed in SARS-CoV-2-infected patients suggests that inflammasomes, pro-inflammatory intracellular complexes, regulate various steps of infection. Lung epithelial cells express inflammasome-forming sensors and constitute the primary entry door of SARS-CoV-2. Here, we describe that the NLRP1 inflammasome detects SARS-CoV-2 infection in human lung epithelial cells. Specifically, human NLRP1 is cleaved at the Q333 site by multiple coronavirus 3CL proteases, which triggers inflammasome assembly, cell death and limits the production of infectious viral particles. Analysis of NLRP1-associated pathways unveils that 3CL proteases also cleave and inactivate the pyroptosis executioner Gasdermin (GSDM)-D. Subsequently, Caspase-3 and GSDM-E promote alternative cell pyroptosis, a process exacerbated in cells exhibiting impaired type I interferon production. Finally, analysis of pyroptosis markers in plasma from COVID-19 patients with characterized severe pneumonia due to Interferon alterations highlight GSDM-E/Caspase-3 as potential markers of disease severity. Overall, our findings identify NLRP1 as a sensor of SARS-CoV-2 infection in lung epithelia. Funding: This project was funded by grants to different co-authors as follows: the Fondation pour la Recherche Médicale (F.R.M.) to E.M. , the ERC StG (INFLAME) to E.M., the ERC StG (ANTIViR) to C.G., and by the French Ministry of Health with the participation of the Groupement Interrégional de Recherche Clinique et d’Innovation Sud-Ouest Outre- Mer (PHRCI 2020 IMMUNOMARK-COV) to G-M.B. The ASB3 structure is supported by LABEX, Investissement d’Avenir and foundation Bettencourt grants to O.N. M.P. and R.P. were respectively funded by a CIFRE PhD fellowship and a research grant from InvivoGen. S.B. is supported by a PhD fellowship from Mali Ministry of Education and from the FRM (FDT 12794). S.A.L.C. is supported by a Vaincre La Mucoviscidose (VLM) PhD fellowship. Declaration of Interests: Authors declare no conflict of interest. Ethics Approval Statement: Clinical data and blood samples for plasma isolation and cryopreservation were collected at the Toulouse University Hospital, France, in the frame of the COVID-BioToul biobank. All donors had given written informed consent and the study was approved by the ethical review board “Comité de Protection des Personnes Est-III” (ID-RCB 2020-A01292-37). Trial Registration: ClinicalTrials.gov Identifier: NCT04385108